CAR T cell immunotherapy for human cancer

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,539

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

CAR-T cell therapy: current limitations and potential strategies

Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926

Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer

Liu, Y., Bhattarai, P., Dai, Z., & Chen, X. S. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00618k · Cited by 2,936

Delivery technologies for cancer immunotherapy

Riley, R., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,678

Chimeric Antigen Receptor Therapy

June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411

Top 10 Challenges in Cancer Immunotherapy

Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238

Development of therapeutic antibodies for the treatment of diseases

Lu, R., Hwang, Y., Liu, I.-J., Lee, C., Tsai, H.-Z., Li, H., & Wu, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,235

IL-6 in inflammation, autoimmunity and cancer

Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453

The evolution of commercial drug delivery technologies

Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361

The current landscape of nucleic acid therapeutics

Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371

Smart cancer nanomedicine

van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F. M., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,279

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

Depil, S., Duchateau, P. N., Grupp, S. A., Mufti, G. J., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,266

Cytokines in clinical cancer immunotherapy

Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberría, I., Aznar, M. A., Perez‐Gracia, J. L., Rodriguez-Ruiz, M. E., Ponz‐Sarvisé, M., Álvarez, E. C., & Melero, I. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,218

A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity

Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149

CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up

Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., Aigner, M., Rothe, T., Minopoulou, I., Tur, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308917 · Cited by 1,178

Targeting STAT3 in Cancer Immunotherapy

Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,109

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdiş, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 1,007

Biopharmaceutical benchmarks 2018

Walsh, G. (2018) · Nature Biotechnology · doi:10.1038/nbt.4305 · Cited by 978

Harnessing innate immunity in cancer therapy

Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957

Mechanisms of resistance to CAR T cell therapy

Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 999

c-Jun overexpression in CAR T cells induces exhaustion resistance

Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891

Enhancing cancer immunotherapy with nanomedicine

Irvine, D. J., & Dane, E. L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 908

Tumor-infiltrating lymphocytes in the immunotherapy era

Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 914

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Martinez, M. C., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 865

Turning cold tumors into hot tumors by improving T-cell infiltration

Liu, Y., & Sun, Z. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 867

TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 + T cell exhaustion

Seo, H., Chen, J., González-Avalos, E., Samaniego-Castruita, D., Das, A., Wang, Y. H., López-Moyado, I. F., Georges, R. O., Zhang, W., Onodera, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905675116 · Cited by 808

Targeting cardiac fibrosis with engineered T cells

Aghajanian, H., Kimura, T., Rurik, J. G., Hancock, A. S., Leibowitz, M. S., Li, L., Scholler, J., Monslow, J., Lo, A., Han, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1546-z · Cited by 801

Natural killer cells in antitumour adoptive cell immunotherapy

Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 810

The future of cancer immunotherapy: microenvironment-targeting combinations

Murciano‐Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 768

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674

Combination strategies to maximize the benefits of cancer immunotherapy

Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654

T cell-engaging therapies — BiTEs and beyond

Goebeler, M.-E., & Bargou, R. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0347-5 · Cited by 675

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Makni‐Maalej, K., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M. A., Maccalli, C., Cherif, H., Shahab Uddin, M. S., Steinhoff, M. S., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 662

Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer

Deepak, K. G. K., Vempati, R. K., Nagaraju, G. P., Dasari, V. R., Nagini, S., Rao, D. N., & Malla, R. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104683 · Cited by 630

Past, present, and future of CRISPR genome editing technologies

Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609

The hallmarks of successful anticancer immunotherapy

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603

Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment

Graham, K., & Unger, E. C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s140462 · Cited by 594

Cancer stemness, intratumoral heterogeneity, and immune response across cancers

Miranda, A., Hamilton, P. T., Zhang, A. W., Pattnaik, S., Becht, É., Mezheyeuski, A., Bruun, J., Micke, P., de Reyniès, A., & Nelson, B. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818210116 · Cited by 581

Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function

Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell · doi:10.1016/j.cell.2018.10.024 · Cited by 573

Cancer stem cells: advances in knowledge and implications for cancer therapy

Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 656

Optimizing oncolytic virotherapy in cancer treatment

Harrington, K. J., Freeman, D. J., Kelly, E. J., Harper, J. A., & Soria, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 530

An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors

Reinhard, K., Rengstl, B., Oehm, P., Michel, K., Billmeier, A., Hayduk, N., Klein, O., Kuna, K., Ouchan, Y., Wöll, S., et al. (2020) · Science · doi:10.1126/science.aay5967 · Cited by 512

Emerging therapies for glioblastoma: current state and future directions

Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 546

Intratumoural administration and tumour tissue targeting of cancer immunotherapies

Melero, I., Álvarez, E. C., Álvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 505

Base editing: advances and therapeutic opportunities

Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W.-M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 499

Emerging new therapeutic antibody derivatives for cancer treatment

Jin, S., Sun, Y., Xiao, L., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 480

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

Parker, K. R., Migliorini, D., Perkey, E., Yost, K. E., Bhaduri, A., Bagga, P., Haris, M., Wilson, N. E., Liu, F., Gabunia, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.022 · Cited by 464

Advances in acute myeloid leukemia

Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 461

Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity

Guo, Y., Xie, Y., Gao, M., Zhao, Y., Franco, F., Wenes, M., Siddiqui, I., Bevilacqua, A., Wang, H., Yang, H., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00940-2 · Cited by 455

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard-Alvarez, A., Grondin, G., Trichard, S., Cesari, C., Sapet, M., Bosco, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.041 · Cited by 451

Engineering the next generation of cell-based therapeutics

Bashor, C. J., Hilton, I. B., Bandukwala, H. S., Smith, D. M., & Omid Veiseh, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 472

Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor

Ma, L., Dichwalkar, T., Chang, J. Y. H., Cossette, B. J., Garafola, D., Zhang, A. Q., Fichter, M., Wang, C., Liang, S., Silva, M., et al. (2019) · Science · doi:10.1126/science.aav8692 · Cited by 439

Supramolecular cancer nanotheranostics

Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411

Paradigms on Immunotherapy Combinations with Chemotherapy

Salas‐Benito, D., Perez‐Gracia, J. L., Ponz‐Sarvisé, M., Rodriguez-Ruiz, M. E., Martínez‐Forero, I., Álvarez, E. C., López-Picazo, J. M., Sanmamed, M. F., & Melero, I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1312 · Cited by 409

Recent advances in nanomaterial-based synergistic combination cancer immunotherapy

Sang, W., Zhang, Z., Dai, Y., & Chen, X. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 409

Adoptive cellular therapies: the current landscape

Rohaan, M. W., Wilgenhof, S., & Haanen, J. B. A. G. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2484-0 · Cited by 422

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

Xu, J., Chen, L., Yang, S., Sun, Y., Wu, W., Liu, Y., Xu, J., Zhuang, Y., Zhang, W., Weng, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819745116 · Cited by 393

γδ T cells: origin and fate, subsets, diseases and immunotherapy

Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 418

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 443

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

Zhang, J., Hu, Y., Yang, J., Li, W., Zhang, M., Wang, Q., Zhang, L., Wei, G., Tian, Y., Zhao, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05140-y · Cited by 397

NK cells switch from granzyme B to death receptor–mediated cytotoxicity during serial killing

Prager, I., Liesche, C., van Ooijen, H., Urlaub, D., Verron, Q., Sandström, N., Fasbender, F., Claus, M., Eils, R., Beaudouin, J., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181454 · Cited by 395

Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy

Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G. R., & Hang, H. C. (2021) · Science · doi:10.1126/science.abc9113 · Cited by 366

Harnessing tumor‐associated macrophages as aids for cancer immunotherapy

Li, X., Liu, R., Su, X., Pan, Y., Han, X., Shao, C., & Shi, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1102-3 · Cited by 364

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

Liu, M., Abad, B. L. D. J., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.021 · Cited by 370

Structural basis of assembly of the human T cell receptor–CD3 complex

Dong, D., Zheng, L., Lin, J., Zhang, B., Zhu, Y., Li, N., Xie, S., Wang, Y., Gao, N., & Huang, Z. (2019) · Nature · doi:10.1038/s41586-019-1537-0 · Cited by 369

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

Nagarsheth, N., Norberg, S. M., Sinkoe, A. L., Adhikary, S., Meyer, T. J., Lack, J., Warner, A., Schweitzer, C., Doran, S. L., Korrapati, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01225-1 · Cited by 357

Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy

Barrett, R. L., & Puré, E. (2020) · eLife · doi:10.7554/elife.57243 · Cited by 357

The approved gene therapy drugs worldwide: from 1998 to 2019

Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310

Biomolecular Condensates and Cancer

Boija, A., Klein, I. A., & Young, R. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.003 · Cited by 338

Biomimetic Nanotechnology toward Personalized Vaccines

Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2019) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 336

Advances in PET imaging of cancer

Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 343

Time to abandon single-site irradiation for inducing abscopal effects

Brooks, E. D., & Chang, J. Y. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 315

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Rodríguez-García, A., Palazón, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01109 · Cited by 326

Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells

Ruf, B., Heinrich, B., & Greten, T. F. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 318

Universal CARs, universal T cells, and universal CAR T cells

Zhao, J., Lin, Q., Song, Y., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0677-2 · Cited by 324

Nanomaterials for T-cell cancer immunotherapy

Gong, N., Sheppard, N. C., Billingsley, M. M., June, C. H., & Mitchell, M. J. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00822-y · Cited by 316

A second-generation M1-polarized CAR macrophage with antitumor efficacy

Lei, A., Yu, H., Lu, S., Lu, H., Ding, X., Tan, T., Zhang, H., Zhu, M., Tian, L., Wang, X., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01687-8 · Cited by 326

Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy

Ye, X., Liang, X., Chen, Q., Miao, Q., Chen, X., Zhang, X., & Mei, L. (2019) · ACS Nano · doi:10.1021/acsnano.8b07371 · Cited by 308

Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy

Phuengkham, H., Ren, L. F., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 306

CAR T cells: Continuation in a revolution of immunotherapy

Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01128-9 · Cited by 303

CAR-T cell therapy for cancer: current challenges and future directions

Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens‐Arias, V., Díaz‐Beyá, M., Juan, M., Urbano-Ispizúa, Á., Esteve, J., Velasco-Hernández, T., & Menéndez, P. R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 350

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma

Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 297

Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses

Chen, Q., Chen, M., & Liu, Z. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00271e · Cited by 291

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

Friedrich, M., Neri, P., Kehl, N., Michel, J., Steiger, S., Kilian, M., Leblay, N., Maity, R., Sankowski, R., Lee, H., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.008 · Cited by 289

Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang, Z., Blum, R. H., Bjordahl, R., Gaidarova, S., Rogers, P., Lee, T. T., Abujarour, R., Bonello, G. B., Wu, J., Tsai, P.-F., et al. (2019) · Blood · doi:10.1182/blood.2019000621 · Cited by 282

Smart Injectable Hydrogels for Cancer Immunotherapy

Chao, Y., Chen, Q., & Liu, Z. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201902785 · Cited by 274

Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors

Park, A. K., Fong, Y., Kim, S., Yang, J., Murad, J. P., Lu, J., Jeang, B., Chang, W.-C., Chen, N. G., Thomas, S. H., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1863 · Cited by 276

Immunotherapy for hepatocellular carcinoma

Zongyi, Y., & Li, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.002 · Cited by 266

Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy

Nam, G., Choi, Y., Kim, G. B., Kim, S., Kim, S. A., & Kim, I. (2020) · Advanced Materials · doi:10.1002/adma.202002440 · Cited by 270

Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view

Huang, X., Lu, Y., Guo, M., Du, S., & Han, N. (2021) · Theranostics · doi:10.7150/thno.56482 · Cited by 267

Cytokines in CAR T Cell–Associated Neurotoxicity

Gust, J., Ponce, R. A., Liles, W. C., Garden, G. A., & Turtle, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577027 · Cited by 279

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

Dafni, U., Michielin, O. A., Lluesma, S. M., Tsourti, Z., Polydoropoulou, V., Karlis, D., Besser, M. J., Haanen, J. B. A. G., Svane, I. M., Ohashi, P. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz398 · Cited by 267

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Wang, N., Hu, X., Cao, W., Li, C., Xiao, Y., Cao, Y., Gu, C., Zhang, S., Chen, L., Cheng, J., et al. (2019) · Blood · doi:10.1182/blood.2019000017 · Cited by 263

Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation

Wu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez‐Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 273

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer

Yu, Y., Zeng, D., Ou, Q., Liu, S., Li, A., Chen, Y., Lin, D., Gao, Q., Zhou, H., Liao, W., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6879 · Cited by 264

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders

Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 328

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial

Reiss, K. A., Angelos, M. G., Dees, E. C., Yuan, Y., Ueno, N. T., Pohlmann, P. R., Johnson, M. L., Chao, J., Shestova, O. E., Serody, J. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03495-z · Cited by 268

Trial Watch: Adoptive cell transfer for oncological indications

Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 33

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3

Abstract KN01: Updates on engineered T cells as cancer therapies

June, C. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-kn01